Skip to content

Study · Randomized controlled trial · 2017

7 results

Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure.

Arturi F, Succurro E, Miceli S, Cloro C, Ruffo M, Maio R, Perticone M, Sesti G, Perticone F

Endocrine9 Nov 2016Cited by 58 (Europe PMC)

PMID27830456 (opens in a new tab)DOI10.1007/s12020-016-1166-4 (opens in a new tab)PepBankPUB-27830456
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes and post-ischemic chronic heart failure, liraglutide improved LVEF from 41.5% to 46.3% over 52 weeks.

    In plain wordsIn people with diabetes and heart failure, liraglutide improved the heart's pumping function compared with before treatment.

    Peptide
    Liraglutide
    Outcome
    IncreaseLeft ventricular ejection fraction (LVEF)
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 52 weeksAs given in this study (human).

    Measurements

    LVEF
    41.5%
    baseline
    LVEF
    46.3%
    after liraglutide

    Source sentences

    Summary
    Liraglutide treatment induced an improvement in left ventricular ejection fraction from 41.5 ± 2.2 to 46.3 ± 3 %; P = 0.001).
    2 context sentences
    Summary · context
    We evaluated 32 type-2 diabetes mellitus Caucasians with history of post-ischemic chronic heart failure NYHA class II/III and/or left ventricular ejection fraction ≤45 %.
    Summary · context
    Patients were treated with standard therapy for chronic heart failure and were randomized to receive liraglutide, sitagliptin and glargine in addition to metformin and/or sulfonylurea.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes and post-ischemic chronic heart failure, indexed end-systolic left ventricular volume fell with liraglutide but not with sitagliptin or glargine.

    In plain wordsIn people with diabetes and heart failure, the heart's end-systolic volume fell with liraglutide but not with the two other drugs.

    Peptide
    Liraglutide
    Outcome
    DecreaseIndexed end-systolic LV volume
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 52 weeksAs given in this study (human).

    Measurements

    Indexed end-systolic LV volume
    51 ml/m2
    baseline
    Indexed end-systolic LV volume
    43 ml/m2
    after liraglutide

    Source sentences

    Summary
    Indexed end-systolic LV volume was reduced only in liraglutide-treated patients (51 ± 9 vs. 43 ± 8 ml/m2; P < 0.05).
    2 context sentences
    Summary · context
    We evaluated 32 type-2 diabetes mellitus Caucasians with history of post-ischemic chronic heart failure NYHA class II/III and/or left ventricular ejection fraction ≤45 %.
    Summary · context
    Patients were treated with standard therapy for chronic heart failure and were randomized to receive liraglutide, sitagliptin and glargine in addition to metformin and/or sulfonylurea.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes and post-ischemic chronic heart failure, liraglutide increased anterograde stroke volume, with no differences in the other two groups.

    In plain wordsIn people with diabetes and heart failure, liraglutide raised the amount of blood pumped per beat, unlike the two other treatments.

    Peptide
    Liraglutide
    Outcome
    IncreaseAnterograde stroke volume
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 52 weeksAs given in this study (human).

    Measurements

    Anterograde stroke volume
    39 ml
    baseline
    Anterograde stroke volume
    49 ml
    after liraglutide

    Source sentences

    Summary
    Liraglutide treatment induced also a significant increase in the anterograde stroke volume (39 ± 9 vs. 49 ± 11 ml; P < 0.05), whereas no differences were observed in the other two groups.
    2 context sentences
    Summary · context
    We evaluated 32 type-2 diabetes mellitus Caucasians with history of post-ischemic chronic heart failure NYHA class II/III and/or left ventricular ejection fraction ≤45 %.
    Summary · context
    Patients were treated with standard therapy for chronic heart failure and were randomized to receive liraglutide, sitagliptin and glargine in addition to metformin and/or sulfonylurea.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes and post-ischemic chronic heart failure, cardiac output increased only in liraglutide-treated patients.

    In plain wordsIn people with diabetes and heart failure, cardiac output rose only in the liraglutide group.

    Peptide
    Liraglutide
    Outcome
    IncreaseCardiac output
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 52 weeksAs given in this study (human).

    Measurements

    Cardiac output
    4.4 L/min
    baseline
    Cardiac output
    5 L/min
    after liraglutide

    Source sentences

    Summary
    Cardiac output and cardiac index showed a significant increase only in liraglutide-treated patients (4.4 ± 0.5 vs. 5.0 ± 0.6 L/min; P 2; P = 0.005, respectively).
    2 context sentences
    Summary · context
    We evaluated 32 type-2 diabetes mellitus Caucasians with history of post-ischemic chronic heart failure NYHA class II/III and/or left ventricular ejection fraction ≤45 %.
    Summary · context
    Patients were treated with standard therapy for chronic heart failure and were randomized to receive liraglutide, sitagliptin and glargine in addition to metformin and/or sulfonylurea.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes and post-ischemic chronic heart failure, cardiac index increased only in liraglutide-treated patients.

    In plain wordsIn people with diabetes and heart failure, cardiac index rose only in the liraglutide group.

    Peptide
    Liraglutide
    Outcome
    IncreaseCardiac index
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 52 weeksAs given in this study (human).

    Measurements

    Cardiac index
    1.23 L/m2
    baseline
    Cardiac index
    1.62 L/m2
    after liraglutide

    Source sentences

    Summary
    Cardiac output and cardiac index showed a significant increase only in liraglutide-treated patients (4.4 ± 0.5 vs. 5.0 ± 0.6 L/min; P 2; P = 0.005, respectively).
    2 context sentences
    Summary · context
    We evaluated 32 type-2 diabetes mellitus Caucasians with history of post-ischemic chronic heart failure NYHA class II/III and/or left ventricular ejection fraction ≤45 %.
    Summary · context
    Patients were treated with standard therapy for chronic heart failure and were randomized to receive liraglutide, sitagliptin and glargine in addition to metformin and/or sulfonylurea.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes and post-ischemic chronic heart failure, liraglutide treatment was associated with improved functional capacity.

    In plain wordsIn people with diabetes and heart failure, liraglutide was linked to better ability to exercise.

    Peptide
    Liraglutide
    Outcome
    IncreaseFunctional capacity
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Exercise and physical function · Whole body
    Studied dose
    Dose not stated · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Liraglutide treatment was also associated with an improvement of functional capacity and an improvement of quality of life.
    2 context sentences
    Summary · context
    We evaluated 32 type-2 diabetes mellitus Caucasians with history of post-ischemic chronic heart failure NYHA class II/III and/or left ventricular ejection fraction ≤45 %.
    Summary · context
    Patients were treated with standard therapy for chronic heart failure and were randomized to receive liraglutide, sitagliptin and glargine in addition to metformin and/or sulfonylurea.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes and post-ischemic chronic heart failure, liraglutide treatment was associated with improved quality of life.

    In plain wordsIn people with diabetes and heart failure, liraglutide was linked to better quality of life.

    Peptide
    Liraglutide
    Outcome
    IncreaseQuality of life
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Quality of life · Whole body
    Studied dose
    Dose not stated · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Liraglutide treatment was also associated with an improvement of functional capacity and an improvement of quality of life.
    2 context sentences
    Summary · context
    We evaluated 32 type-2 diabetes mellitus Caucasians with history of post-ischemic chronic heart failure NYHA class II/III and/or left ventricular ejection fraction ≤45 %.
    Summary · context
    Patients were treated with standard therapy for chronic heart failure and were randomized to receive liraglutide, sitagliptin and glargine in addition to metformin and/or sulfonylurea.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.